VICORE PHARMA HOLDING AB ADR
VCRENASDAQπ #3234 by market capUS Equity
ββ
Quote unavailableTrack VCRE
Get earnings, price moves & breaking news on Telegram
24hβ
7dβ
14dβ
30dβ
ytdβ
1yβ
π¦Market Cap
$275M
Small Cap
πRevenue Growth (YoY)
-48.4%
Declining
πGross Margin
360.3%
High
π΅FCF Margin
β
βοΈP/S Ratio
700.3x
Expensive
Otter Score
36
Weak
No chart data available for VCRE.
Trading Snapshot
- Day Range
- β
- 52-Week Range
- β
- Volume (shares)
- β
- Avg Volume (shares)
- β
- Shares Outstanding
- 281.6M
- Next Earnings
- β
Fundamentals Snapshot
- Annual Revenue
- $4M
- Last Q Revenue
- $228,246
- P/E Ratio
- β
- P/S Ratio
- 700.3x
- EPS (TTM)
- β
- Dividend Yield
- β
- Dilution (1yr)
- +18.4%
VICORE PHARMA HOLDING AB ADR
VCREFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$4MβΌ β96.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%β² +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnβt profitable yet.
β$454Mβ² +138.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
β$376Mβ² +127.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerβs slice.
25.6Mβ² +18.4% YoY
About VICORE PHARMA HOLDING AB ADR
Vicore Pharma Holding AB is a pharmaceutical company, which engages in the development of drugs with focus on interstitial lung diseases and related indications. Its drug development programs include VP01, VP02, VP03, and VP04. The company was founded in 2000 sand is headquartered in Stockholm, Sweden.
π¦¦
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)πQualityβ
β
β
β
β
πGrowthβ
β
β
β
β
βοΈValuationβ
β
β
β
β
β‘Momentumβ
β
β
β
β
π§Dilutionβ
β
β
β
β
Overall Score
Weak
36/100
Analyst data unavailable.
Latest News & Updates
News unavailable.